Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Squamous Cell Carcinoma of Head and Neck 22Uterine Cervical Neoplasms 19Lung Neoplasms 19Small Cell Lung Carcinoma 16Oropharyngeal Neoplasms 14Ovarian Neoplasms 12Carcinoma 10Urinary Bladder Neoplasms 9Stomach Neoplasms 9Mouth Neoplasms 9Laryngeal Neoplasms 9Fallopian Tube Neoplasms 9Hypopharyngeal Neoplasms 8Mesothelioma, Malignant 7Medulloblastoma 7Cholangiocarcinoma 7Breast Neoplasms 7Adenocarcinoma of Lung 7Pancreatic Neoplasms 6Neuroblastoma 6Nasopharyngeal Carcinoma 6Gallbladder Neoplasms 6Ganglioneuroblastoma 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Lymphoid Interstitial Pneumonia 4Head and Neck Neoplasms 4Esophageal Neoplasms 4

Interventions

Etoposide 3Carboplatin 3Paclitaxel 2sintilimab 1pembrolizumab 1olaparib 1ceralasertib 1atezolizumab 1apatinib 1anlotinib 1Topotecan 1Platinum 1Immune Checkpoint Inhibitors 1Drug Therapy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
SCLC × Platinum × Clear all
NCT05844150 2025-03-12

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Biotheus Inc.

Phase 2 Active not recruiting
50 enrolled
Thoracic

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡